The Evolving Treatment Landscape in Hepatocellular Carcinoma: New Agents and the Role of Biomarkers in First-Line Treatment Evaluation (ID: i750a) Question Title * 1. What would be your preferred regimen when referring patients to clinical trials for first-line treatment of HCC? Nivolumab + Ipilimumab (CheckMate 9DW) Lenvatinib + Pembrolizumab (LEAP-002) Atezolizumab + Bevacizumab (IMbrave 150) I do not refer to clinical trials/not in clinical practice Question Title * 2. Following participation in this activity, how confident are in you the management of patients with HCC? Very confident Confident Neutral Little confidence No confidence Question Title * 3. How many years have you been in practice? >21 11-20 1-10 <1 Question Title * 4. How many patients with HCC do you treat each week? 1 to 10 11 to 25 26 to 50 I am not directly involved in patient care Question Title * 5. Please select the option that best describes your practice: Academic Clinician Community Clinician Other (please specify) Question Title * 6. How committed are you to making changes in your practice based on your participation in this activity Very committed Committed Neutral Not committed I do not plan to make changes Question Title * 7. After participating in today’s activity, I am now able to: Strongly agree Agree Neutral Disagree Strongly disagree Discuss efficacy and safety data from key clinical trials evaluating the use of new agents in first-line HCC treatment settings Discuss efficacy and safety data from key clinical trials evaluating the use of new agents in first-line HCC treatment settings Strongly agree Discuss efficacy and safety data from key clinical trials evaluating the use of new agents in first-line HCC treatment settings Agree Discuss efficacy and safety data from key clinical trials evaluating the use of new agents in first-line HCC treatment settings Neutral Discuss efficacy and safety data from key clinical trials evaluating the use of new agents in first-line HCC treatment settings Disagree Discuss efficacy and safety data from key clinical trials evaluating the use of new agents in first-line HCC treatment settings Strongly disagree Implement strategies to identify, monitor, and manage treatment-related AEs Implement strategies to identify, monitor, and manage treatment-related AEs Strongly agree Implement strategies to identify, monitor, and manage treatment-related AEs Agree Implement strategies to identify, monitor, and manage treatment-related AEs Neutral Implement strategies to identify, monitor, and manage treatment-related AEs Disagree Implement strategies to identify, monitor, and manage treatment-related AEs Strongly disagree Question Title * 8. The content presented: Strongly agree Agree Neutral Disagree Strongly disagree Enhanced my current knowledge base Enhanced my current knowledge base Strongly agree Enhanced my current knowledge base Agree Enhanced my current knowledge base Neutral Enhanced my current knowledge base Disagree Enhanced my current knowledge base Strongly disagree Addressed my most pressing questions Addressed my most pressing questions Strongly agree Addressed my most pressing questions Agree Addressed my most pressing questions Neutral Addressed my most pressing questions Disagree Addressed my most pressing questions Strongly disagree Promoted improvements or quality in health care Promoted improvements or quality in health care Strongly agree Promoted improvements or quality in health care Agree Promoted improvements or quality in health care Neutral Promoted improvements or quality in health care Disagree Promoted improvements or quality in health care Strongly disagree Was scientifically rigorous and evidence based Was scientifically rigorous and evidence based Strongly agree Was scientifically rigorous and evidence based Agree Was scientifically rigorous and evidence based Neutral Was scientifically rigorous and evidence based Disagree Was scientifically rigorous and evidence based Strongly disagree Question Title * 9. This activity was free from commercial bias. Yes No Question Title * 10. If you indicated that you perceived commercial bias or influence, please describe: Question Title * 11. As a result of your participation in this activity, what is the one change you are most likely to implement in your practice? Question Title * 12. What barriers do you see to making changes in your practice? Lack of knowledge regarding evidence-based strategies Lack of convincing evidence to warrant change Lack of time/resources to consider change Insurance, reimbursement, or legal issues Conflicting guidelines and/or evidence Patient compliance and/or patient resource barriers Other (please specify) Question Title * 13. Please list any clinical issues/problems within your scope of practice you would like to see addressed in future educational activities: Done